pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
IPSEN · news · pharmadog
← back to IPSEN
News mentioning IPSEN
17
stories
14h
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
18h
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
biospace
3d
Slate, Fulcrum to combine in reverse merger
biopharma dive
6d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
21d
Ipsen has 'firepower' for more deals with €2B war chest
endpoints
27d
Ipsen’s Bylvay fails key trial in children with rare liver disease
endpoints
Jul 13, 26
Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
endpoints
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
Jul 9, 26
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
endpoints
Jul 7, 26
Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first half
endpoints
Jul 1, 26
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
biopharma dive
Jul 1, 26
STAT+: More signs that GLP-1s may help with peripheral artery disease
stat
Jul 1, 26
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
endpoints
Jun 30, 26
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
biopharma dive
Jun 29, 26
Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
endpoints
Jun 2, 26
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
biopharma dive
Jun 2, 26
Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
endpoints
